Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference [Yahoo! Finance]
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference